Exhaustive de novo Design of Low-Molecular-Weight Fragments Against the ATP-Binding Site of DNA-Gyrase

2006 ◽  
Vol 46 (3) ◽  
pp. 1168-1173 ◽  
Author(s):  
Stuart Firth-Clark ◽  
Nikolay P. Todorov ◽  
Ian L. Alberts ◽  
Anthony Williams ◽  
Timothy James ◽  
...  
ChemInform ◽  
2006 ◽  
Vol 37 (30) ◽  
Author(s):  
Stuart Firth-Clark ◽  
Nikolay P. Todorov ◽  
Ian L. Alberts ◽  
Anthony Williams ◽  
Timothy James ◽  
...  

2015 ◽  
Vol 58 (14) ◽  
pp. 5501-5521 ◽  
Author(s):  
Tihomir Tomašič ◽  
Sotirios Katsamakas ◽  
Žiga Hodnik ◽  
Janez Ilaš ◽  
Matjaž Brvar ◽  
...  

2006 ◽  
Vol 349 (4) ◽  
pp. 1206-1213 ◽  
Author(s):  
Marko Oblak ◽  
Simona Golič Grdadolnik ◽  
Miha Kotnik ◽  
Arnaud Poterszman ◽  
R. Andrew Atkinson ◽  
...  

2007 ◽  
Vol 50 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Helena Gradišar ◽  
Primož Pristovšek ◽  
Andreja Plaper ◽  
Roman Jerala

2017 ◽  
Vol 125 ◽  
pp. 500-514 ◽  
Author(s):  
Marko Jukič ◽  
Janez Ilaš ◽  
Matjaž Brvar ◽  
Danijel Kikelj ◽  
Jožko Cesar ◽  
...  

2015 ◽  
Vol 43 (3) ◽  
pp. 1444-1455 ◽  
Author(s):  
Jianke Ren ◽  
Victorino Briones ◽  
Samantha Barbour ◽  
Weishi Yu ◽  
Yixing Han ◽  
...  

2004 ◽  
Vol 47 (18) ◽  
pp. 4373-4390 ◽  
Author(s):  
Martina Schechner ◽  
Finton Sirockin ◽  
Roland H. Stote ◽  
Annick P. Dejaegere

2019 ◽  
Vol 19 (11) ◽  
pp. 914-926 ◽  
Author(s):  
Maiara Bernardes Marques ◽  
Michael González-Durruthy ◽  
Bruna Félix da Silva Nornberg ◽  
Bruno Rodrigues Oliveira ◽  
Daniela Volcan Almeida ◽  
...  

Background:PIM-1 is a kinase which has been related to the oncogenic processes like cell survival, proliferation, and multidrug resistance (MDR). This kinase is known for its ability to phosphorylate the main extrusion pump (ABCB1) related to the MDR phenotype.Objective:In the present work, we tested a new mechanistic insight on the AZD1208 (PIM-1 specific inhibitor) under interaction with chemotherapy agents such as Daunorubicin (DNR) and Vincristine (VCR).Materials and Methods:In order to verify a potential cytotoxic effect based on pharmacological synergism, two MDR cell lines were used: Lucena (resistant to VCR) and FEPS (resistant to DNR), both derived from the K562 non-MDR cell line, by MTT analyses. The activity of Pgp was ascertained by measuring accumulation and the directional flux of Rh123. Furthermore, we performed a molecular docking simulation to delve into the molecular mechanism of PIM-1 alone, and combined with chemotherapeutic agents (VCR and DNR).Results:Our in vitro results have shown that AZD1208 alone decreases cell viability of MDR cells. However, co-exposure of AZD1208 and DNR or VCR reverses this effect. When we analyzed the ABCB1 activity AZD1208 alone was not able to affect the pump extrusion. Differently, co-exposure of AZD1208 and DNR or VCR impaired ABCB1 activity, which could be explained by compensatory expression of abcb1 or other extrusion pumps not analyzed here. Docking analysis showed that AZD1208 is capable of performing hydrophobic interactions with PIM-1 ATP- binding-site residues with stronger interaction-based negative free energy (FEB, kcal/mol) than the ATP itself, mimicking an ATP-competitive inhibitory pattern of interaction. On the same way, VCR and DNR may theoretically interact at the same biophysical environment of AZD1208 and also compete with ATP by the PIM-1 active site. These evidences suggest that AZD1208 may induce pharmacodynamic interaction with VCR and DNR, weakening its cytotoxic potential in the ATP-binding site from PIM-1 observed in the in vitro experiments.Conclusion:Finally, the current results could have a pre-clinical relevance potential in the rational polypharmacology strategies to prevent multiple-drugs resistance in human leukemia cancer therapy.


1994 ◽  
Vol 269 (21) ◽  
pp. 14962-14966
Author(s):  
M. Pavela-Vrancic ◽  
E. Pfeifer ◽  
W. Schröder ◽  
H. von Döhren ◽  
H. Kleinkauf

Sign in / Sign up

Export Citation Format

Share Document